Neutralizing antibodies to HIV-1 induced by immunization

Laura E McCoy, Robin A Weiss, Laura E McCoy, Robin A Weiss

Abstract

Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV has been revolutionized by the isolation of extremely broad and potent neutralizing antibodies from HIV-infected individuals. Considerable hurdles remain for inducing neutralizing antibodies to a protective level after immunization. Meanwhile, novel technologies to bypass the induction of antibodies are being explored to provide prophylactic antibody-based interventions. This review addresses the challenge of inducing HIV neutralizing antibodies upon immunization and considers notable recent advances in the field. A greater understanding of the successes and failures for inducing a neutralizing response upon immunization is required to accelerate the development of an effective HIV vaccine.

Figures

Figure 1.
Figure 1.
Neutralizing mAbs targeting HIV Env. The diagram was adapted from Burton and Weiss (2010).

References

    1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., et al. ; CAPRISA 004 Trial Group 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329:1168–1174 10.1126/science.1193748
    1. Ahmed F.K., Clark B.E., Burton D.R., Pantophlet R. 2012. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine. 30:922–930 10.1016/j.vaccine.2011.11.089
    1. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., Rits-Volloch S., Sun L., Harrison S.C., Haynes B.F., Chen B. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 106:20234–20239 10.1073/pnas.0908713106
    1. Andrus L., Prince A.M., Bernal I., McCormack P., Lee D.H., Gorny M.K., Zolla-Pazner S. 1998. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J. Infect. Dis. 177:889–897 10.1086/515251
    1. Arnold G.F., Velasco P.K., Holmes A.K., Wrin T., Geisler S.C., Phung P., Tian Y., Resnick D.A., Ma X., Mariano T.M., et al. 2009. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 83:5087–5100 10.1128/JVI.00184-09
    1. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 481:81–84 10.1038/nature10660
    1. Barbato G., Bianchi E., Ingallinella P., Hurni W.H., Miller M.D., Ciliberto G., Cortese R., Bazzo R., Shiver J.W., Pessi A. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:1101–1115 10.1016/S0022-2836(03)00611-9
    1. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Haynes J.R., Walker C.M., Steimer K.S. 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine. 15:869–873 10.1016/S0264-410X(96)00264-2
    1. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., et al. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526–5540 10.1128/JVI.75.12.5526-5540.2001
    1. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., Ferrai M.G., Weiss D.E., Letvin N.L., Montefiori D., et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS. 22:339–348 10.1097/QAD.0b013e3282f3ca57
    1. Barnett S.W., Burke B., Sun Y., Kan E., Legg H., Lian Y., Bost K., Zhou F., Goodsell A., Zur Megede J., et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975–5985 10.1128/JVI.02533-09
    1. Barouch D.H. 2010. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 5:386–390 10.1097/COH.0b013e32833cfe4c
    1. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., Iampietro M.J., SanMiguel A., Seaman M.S., Ferrari G., et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 482:89–93 10.1038/nature10766
    1. Bartlett J.A., Wasserman S.S., Hicks C.B., Dodge R.T., Weinhold K.J., Tacket C.O., Ketter N., Wittek A.E., Palker T.J., Haynes B.F.; Division of AIDS Treatment Research Initiative 1998. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. AIDS. 12:1291–1300 10.1097/00002030-199811000-00010
    1. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., et al. 2007. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 360:329–340 10.1016/j.virol.2006.10.032
    1. Beirnaert E., Nyambi P., Willems B., Heyndrickx L., Colebunders R., Janssens W., van der Groen G. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14–24 10.1002/1096-9071(200009)62:1<14::AID-JMV3>;2-L
    1. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., Wilson I.A. 2008. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 375:969–978 10.1016/j.jmb.2007.11.013
    1. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.L., Duliege A.M., Tartaglia J., Cox W.I., McNamara J., et al. ; NIAID AIDS Vaccine Evaluation Group 1998. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 12:2407–2415 10.1097/00002030-199818000-00009
    1. Berman P.W., Groopman J.E., Gregory T., Clapham P.R., Weiss R.A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L.A., et al. 1988. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 85:5200–5204 10.1073/pnas.85.14.5200
    1. Berman P.W., Gregory T.J., Riddle L., Nakamura G.R., Champe M.A., Porter J.P., Wurm F.M., Hershberg R.D., Cobb E.K., Eichberg J.W. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:622–625 10.1038/345622a0
    1. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232–13252 10.1128/JVI.78.23.13232-13252.2004
    1. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651–11668 10.1128/JVI.01762-08
    1. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., Mortier D., Lian Y., Oostermeijer H., Fagrouch Z., et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 382:217–225 10.1016/j.virol.2008.09.016
    1. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., Desgranges C. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity. 9:277–287 10.1016/S1074-7613(00)80610-X
    1. Bonsignori M., Montefiori D.C., Wu X., Chen X., Hwang K.K., Tsao C.Y., Kozink D.M., Parks R.J., Tomaras G.D., Crump J.A., et al. 2012. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86:4688–4692 10.1128/JVI.07163-11
    1. Bower J.F., Yang X., Sodroski J., Ross T.M. 2004. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J. Virol. 78:4710–4719 10.1128/JVI.78.9.4710-4719.2004
    1. Burke B., Barnett S.W. 2007. Broadening our view of protective antibody responses against HIV. Curr. HIV Res. 5:625–641 10.2174/157016207782418533
    1. Burton D.R., Weiss R.A. 2010. AIDS/HIV. A boost for HIV vaccine design. Science. 329:770–773 10.1126/science.1194693
    1. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1024–1027 10.1126/science.7973652
    1. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 337:183–186 10.1126/science.1225416
    1. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300:2065–2071 10.1126/science.1083182
    1. Chaillon A., Braibant M., Moreau T., Thenin S., Moreau A., Autran B., Barin F. 2011. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J. Virol. 85:3642–3648 10.1128/JVI.02424-10
    1. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., King S.R., Montefiori D.C., Nabel G.J. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357–5368 10.1128/JVI.76.11.5357-5368.2002
    1. Chakrabarti B.K., Ling X., Yang Z.Y., Montefiori D.C., Panet A., Kong W.P., Welcher B., Louder M.K., Mascola J.R., Nabel G.J. 2005. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine. 23:3434–3445 10.1016/j.vaccine.2005.01.099
    1. Connor R.I., Korber B.T., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., et al. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552–1576
    1. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE. 5:e8805 10.1371/journal.pone.0008805
    1. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., Hunt P., McCune J.M., Martin J.N., Petropoulos C.J., Hecht F.M. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80:6155–6164 10.1128/JVI.00093-06
    1. Dennison S.M., Sutherland L.L., Jaeger F.H., Anasti K.M., Parks R., Stewart S., Bowman C., Xia S.M., Zhang R., Shen X., et al. 2011. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE. 6:e27824 10.1371/journal.pone.0027824
    1. Devito C., Zuber B., Schröder U., Benthin R., Okuda K., Broliden K., Wahren B., Hinkula J. 2004. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173:7078–7089
    1. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., Burton D.R. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548–6562 10.1128/JVI.02749-06
    1. Dimitrov J.D., Kazatchkine M.D., Kaveri S.V., Lacroix-Desmazes S. 2011. “Rational vaccine design” for HIV should take into account the adaptive potential of polyreactive antibodies. PLoS Pathog. 7:e1002095 10.1371/journal.ppat.1002095
    1. Diskin R., Scheid J.F., Marcovecchio P.M., West A.P., Jr, Klein F., Gao H., Gnanapragasam P.N., Abadir A., Seaman M.S., Nussenzweig M.C., Bjorkman P.J. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334:1289–1293 10.1126/science.1213782
    1. Dong M., Zhang P.F., Grieder F., Lee J., Krishnamurthy G., VanCott T., Broder C., Polonis V.R., Yu X.F., Shao Y., et al. 2003. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol. 77:3119–3130 10.1128/JVI.77.5.3119-3130.2003
    1. Doria-Rose N.A., Louder M.K., Yang Z., O’Dell S., Nason M., Schmidt S.D., McKee K., Seaman M.S., Bailer R.T., Mascola J.R. 2012. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86:3393–3397 10.1128/JVI.06745-11
    1. Douagi I., Forsell M.N., Sundling C., O’Dell S., Feng Y., Dosenovic P., Li Y., Seder R., Loré K., Mascola J.R., et al. 2010. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J. Virol. 84:1683–1695 10.1128/JVI.01896-09
    1. Durda P.J., Leece B., Jenoski A., Rabin H., Fisher A., Wong-Staal F. 1988. Characterization of murine monoclonal antibodies to HIV-1 induced by synthetic peptides. AIDS Res. Hum. Retroviruses. 4:331–342 10.1089/aid.1988.4.331
    1. Earl P.L., Robert-Guroff M., Matthews T.J., Krohn K., London W.T., Moss B. 1989. Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Hum. Retroviruses. 5:23–32 10.1089/aid.1989.5.23
    1. Falkowska E., Ramos A., Feng Y., Zhou T., Moquin S., Walker L.M., Wu X., Seaman M.S., Wrin T., Kwong P.D., et al. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394–4403 10.1128/JVI.06973-11
    1. Ferrantelli F., Maggiorella M.T., Schiavoni I., Sernicola L., Olivieri E., Farcomeni S., Pavone-Cossut M.R., Moretti S., Belli R., Collacchi B., et al. 2011. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine. 29:2918–2932 10.1016/j.vaccine.2011.02.006
    1. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F.; rgp120 HIV Vaccine Study Group 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654–665 10.1086/428404
    1. Forsell M.N., Li Y., Sundbäck M., Svehla K., Liljeström P., Mascola J.R., Wyatt R., Karlsson Hedestam G.B. 2005. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J. Virol. 79:10902–10914 10.1128/JVI.79.17.10902-10914.2005
    1. Forsell M.N., Schief W.R., Wyatt R.T. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS. 4:380–387 10.1097/COH.0b013e32832edc19
    1. Forsman A., Beirnaert E., Aasa-Chapman M.M., Hoorelbeke B., Hijazi K., Koh W., Tack V., Szynol A., Kelly C., McKnight A., et al. 2008. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 82:12069–12081 10.1128/JVI.01379-08
    1. Forthal D.N., Moog C. 2009. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 4:388–393 10.1097/COH.0b013e32832f0a89
    1. Gilbert P., Wang M., Wrin T., Petropoulos C., Gurwith M., Sinangil F., D’Souza P., Rodriguez-Chavez I.R., DeCamp A., Giganti M., et al. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595–605 10.1086/654816
    1. Gorlani A., Brouwers J., McConville C., van der Bijl P., Malcolm K., Augustijns P., Quigley A.F., Weiss R., De Haard H., Verrips T. 2012. Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res. Hum. Retroviruses. 28:198–205 10.1089/aid.2011.0133
    1. Gorse G.J., McElrath M.J., Matthews T.J., Hsieh R.H., Belshe R.B., Corey L., Frey S.E., Kennedy D.J., Walker M.C., Eibl M.M.; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group 1998. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 16:493–506 10.1016/S0264-410X(97)80003-5
    1. Graham B.S., Keefer M.C., McElrath M.J., Gorse G.J., Schwartz D.H., Weinhold K., Matthews T.J., Esterlitz J.R., Sinangil F., Fast P.E.; NIAID AIDS Vaccine Evaluation Group 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann. Intern. Med. 125:270–279
    1. Gray E.S., Madiga M.C., Hermanus T., Moore P.L., Wibmer C.K., Tumba N.L., Werner L., Mlisana K., Sibeko S., Williamson C., et al. ; and the CAPRISA002 Study Team 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85:4828–4840 10.1128/JVI.00198-11
    1. Haigwood N.L., Shuster J.R., Moore G.K., Lee H., Skiles P.V., Higgins K.W., Barr P.J., George-Nascimento C., Steimer K.S. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses. 6:855–869 10.1089/aid.1990.6.855
    1. Hammonds J., Chen X., Fouts T., DeVico A., Montefiori D., Spearman P. 2005. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 79:14804–14814 10.1128/JVI.79.23.14804-14814.2005
    1. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275–1286 10.1056/NEJMoa1113425
    1. Hessell A.J., Haigwood N.L. 2012. Neutralizing antibodies and control of HIV: moves and countermoves. Curr. HIV/AIDS Rep. 9:64–72 10.1007/s11904-011-0105-5
    1. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433 10.1371/journal.ppat.1000433
    1. Ho D.D., Kaplan J.C., Rackauskas I.E., Gurney M.E. 1988. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science. 239:1021–1023 10.1126/science.2830667
    1. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 491:406–412 10.1038/nature11544
    1. Jain S., Rosenthal K.L. 2011. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol. 4:539–553 10.1038/mi.2011.21
    1. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., Desrosiers R.C., Clark K.R. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:901–906 10.1038/nm.1967
    1. Joyce J.G., Krauss I.J., Song H.C., Opalka D.W., Grimm K.M., Nahas D.D., Esser M.T., Hrin R., Feng M., Dudkin V.Y., et al. 2008. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. USA. 105:15684–15689 10.1073/pnas.0807837105
    1. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., Liao H.X. 2005. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res. Hum. Retroviruses. 21:58–67 10.1089/aid.2005.21.58
    1. Klasse P.J., Sanders R.W., Cerutti A., Moore J.P. 2012. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res. Hum. Retroviruses. 28:1–15 10.1089/aid.2011.0053
    1. Klein F., Gaebler C., Mouquet H., Sather D.N., Lehmann C., Scheid J.F., Kraft Z., Liu Y., Pietzsch J., Hurley A., et al. 2012a. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209:1469–1479 10.1084/jem.20120423
    1. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., et al. 2012b. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 492:118–122
    1. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., Seaman M.S., Barouch D.H., Chen B. 2012. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. USA. 109:12111–12116 10.1073/pnas.1204533109
    1. Kwong P.D., Mascola J.R., Nabel G.J. 2012. The changing face of HIV vaccine research. J. Int. AIDS Soc. 15:17407.
    1. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557–10565 10.1128/JVI.77.19.10557-10565.2003
    1. Lagenaur L.A., Villarroel V.A., Bundoc V., Dey B., Berger E.A. 2010. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology. 7:11 10.1186/1742-4690-7-11
    1. Lai R.P., Seaman M.S., Tonks P., Wegmann F., Seilly D.J., Frost S.D., LaBranche C.C., Montefiori D.C., Dey A.K., Srivastava I.K., et al. 2012. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund’s adjuvants. PLoS ONE. 7:e35083 10.1371/journal.pone.0035083
    1. Lakhashe S.K., Velu V., Sciaranghella G., Siddappa N.B., Dipasquale J.M., Hemashettar G., Yoon J.K., Rasmussen R.A., Yang F., Lee S.J., et al. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 29:5611–5622 10.1016/j.vaccine.2011.06.017
    1. Law M., Cardoso R.M., Wilson I.A., Burton D.R. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81:4272–4285 10.1128/JVI.02536-06
    1. Lewis A.D., Chen R., Montefiori D.C., Johnson P.R., Clark K.R. 2002. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J. Virol. 76:8769–8775 10.1128/JVI.76.17.8769-8775.2002
    1. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., Montefiori D., Polacino P., Hu S.L. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82:638–651 10.1128/JVI.01691-07
    1. Li Y., O’Dell S., Walker L.M., Wu X., Guenaga J., Feng Y., Schmidt S.D., McKee K., Louder M.K., Ledgerwood J.E., et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954–8967 10.1128/JVI.00754-11
    1. Lian Y., Srivastava I., Gómez-Román V.R., Zur Megede J., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P.A., et al. 2005. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79:13338–13349 10.1128/JVI.79.21.13338-13349.2005
    1. Lorin C., Mollet L., Delebecque F., Combredet C., Hurtrel B., Charneau P., Brahic M., Tangy F. 2004. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78:146–157 10.1128/JVI.78.1.146-157.2004
    1. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M., Jr, et al. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651–658 10.1038/nm0697-651
    1. Lynch R.M., Tran L., Louder M.K., Schmidt S.D., Cohen M., Dersimonian R., Euler Z., Gray E.S., Abdool Karim S., Kirchherr J., et al. ; CHAVI 001 Clinical Team Members 2012. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86:7588–7595 10.1128/JVI.00734-12
    1. Ma B.J., Alam S.M., Go E.P., Lu X., Desaire H., Tomaras G.D., Bowman C., Sutherland L.L., Scearce R.M., Santra S., et al. 2011. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 7:e1002200 10.1371/journal.ppat.1002200
    1. Malherbe D.C., Doria-Rose N.A., Misher L., Beckett T., Puryear W.B., Schuman J.T., Kraft Z., O’Malley J., Mori M., Srivastava I., et al. 2011. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85:5262–5274 10.1128/JVI.02419-10
    1. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., et al. ; The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340–348 10.1093/infdis/173.2.340
    1. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009–4018
    1. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207–210 10.1038/72318
    1. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., Vancott T.C., Huang Y., Chakrabarti B.K., Kong W.P., et al. 2005. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79:771–779 10.1128/JVI.79.2.771-779.2005
    1. McBurney S.P., Young K.R., Ross T.M. 2007. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology. 358:334–346 10.1016/j.virol.2006.08.032
    1. McCoy L.E., Quigley A.F., Strokappe N.M., Bulmer-Thomas B., Seaman M.S., Mortier D., Rutten L., Chander N., Edwards C.J., Ketteler R., et al. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209:1091–1103 10.1084/jem.20112655
    1. McElrath M.J., Haynes B.F. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 33:542–554 10.1016/j.immuni.2010.09.011
    1. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 480:336–343 10.1038/nature10696
    1. McMichael A.J., Haynes B.F. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423–427 10.1038/ni.2264
    1. Mehandru S., Wrin T., Galovich J., Stiegler G., Vcelar B., Hurley A., Hogan C., Vasan S., Katinger H., Petropoulos C.J., Markowitz M. 2004. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 78:14039–14042 10.1128/JVI.78.24.14039-14042.2004
    1. Moir S., Malaspina A., Fauci A.S. 2011. Prospects for an HIV vaccine: leading B cells down the right path. Nat. Struct. Mol. Biol. 18:1317–1321 10.1038/nsmb.2194
    1. Moldt B., Shibata-Koyama M., Rakasz E.G., Schultz N., Kanda Y., Dunlop D.C., Finstad S.L., Jin C., Landucci G., Alpert M.D., et al. 2012. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86:6189–6196 10.1128/JVI.00491-12
    1. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., McLinden R., Tovanabutra S., Laurence-Chenine A., Sanders-Buell E., et al. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431–441 10.1093/infdis/jis367
    1. Mörner A., Douagi I., Forsell M.N., Sundling C., Dosenovic P., O’Dell S., Dey B., Kwong P.D., Voss G., Thorstensson R., et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540–551 10.1128/JVI.01102-08
    1. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., et al. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA. 99:6913–6918 10.1073/pnas.102562599
    1. Murphy K. 2011. The distribution and functions of immunoglobulin isotypes. In Janeway’s Immunobiology. 8th edition Garland Science, New York: 408–417
    1. Nara P.L., Robey W.G., Pyle S.W., Hatch W.C., Dunlop N.M., Bess J.W., Jr, Kelliher J.C., Arthur L.O., Fischinger P.J. 1988. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J. Virol. 62:2622–2628
    1. Ndung’u T., Weiss R.A. 2012. On HIV diversity. AIDS. 26:1255–1260 10.1097/QAD.0b013e32835461b5
    1. Nelson J.D., Kinkead H., Brunel F.M., Leaman D., Jensen R., Louis J.M., Maruyama T., Bewley C.A., Bowdish K., Clore G.M., et al. 2008. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology. 377:170–183 10.1016/j.virol.2008.04.005
    1. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Donau O.K., Buckler C., Plishka R.J., Buckler-White A., Martin M.A. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA. 100:15131–15136 10.1073/pnas.2436476100
    1. Nishiyama Y., Planque S., Mitsuda Y., Nitti G., Taguchi H., Jin L., Symersky J., Boivin S., Sienczyk M., Salas M., et al. 2009. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J. Biol. Chem. 284:30627–30642 10.1074/jbc.M109.032185
    1. Pantaleo G., Esteban M., Jacobs B., Tartaglia J. 2010. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS. 5:391–396 10.1097/COH.0b013e32833d1e87
    1. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340–8347 10.1128/JVI.75.17.8340-8347.2001
    1. Pejchal R., Wilson I.A. 2010. Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16:3744–3753 10.2174/138161210794079173
    1. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 334:1097–1103 10.1126/science.1213256
    1. Picker L.J., Hansen S.G., Lifson J.D. 2012. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63:95–111 10.1146/annurev-med-042010-085643
    1. Pincus S.H., Messer K.G., Cole R., Ireland R., VanCott T.C., Pinter A., Schwartz D.H., Graham B.S., Gorse G.J. 1997. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. 158:3511–3520
    1. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K.; Bangkok Vaccine Evaluation Group 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661–1671 10.1086/508748
    1. Plotkin S.A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401–409 10.1086/589862
    1. Poignard P., Sabbe R., Picchio G.R., Wang M., Gulizia R.J., Katinger H., Parren P.W., Mosier D.E., Burton D.R. 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 10:431–438 10.1016/S1074-7613(00)80043-6
    1. Poon B., Hsu J.F., Gudeman V., Chen I.S., Grovit-Ferbas K. 2005. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J. Virol. 79:10210–10217 10.1128/JVI.79.16.10210-10217.2005
    1. Quinnan G.V., Jr, Yu X.F., Lewis M.G., Zhang P.F., Sutter G., Silvera P., Dong M., Choudhary A., Sarkis P.T., Bouma P., et al. 2005. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J. Virol. 79:3358–3369 10.1128/JVI.79.6.3358-3369.2005
    1. Radaelli A., Bonduelle O., Beggio P., Mahe B., Pozzi E., Elli V., Paganini M., Zanotto C., De Giuli Morghen C., Combadière B. 2007. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine. 25:2128–2138 10.1016/j.vaccine.2006.11.009
    1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. ; MOPH-TAVEG Investigators 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209–2220 10.1056/NEJMoa0908492
    1. Robert-Guroff M., Brown M., Gallo R.C. 1985. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 316:72–74 10.1038/316072a0
    1. Robey W.G., Arthur L.O., Matthews T.J., Langlois A., Copeland T.D., Lerche N.W., Oroszlan S., Bolognesi D.P., Gilden R.V., Fischinger P.J. 1986. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc. Natl. Acad. Sci. USA. 83:7023–7027 10.1073/pnas.83.18.7023
    1. Rollman E., Hinkula J., Arteaga J., Zuber B., Kjerrström A., Liu M., Wahren B., Ljungberg K. 2004. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 11:1146–1154 10.1038/sj.gt.3302275
    1. Rosen O., Chill J., Sharon M., Kessler N., Mester B., Zolla-Pazner S., Anglister J. 2005. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry. 44:7250–7258 10.1021/bi047387t
    1. Russell N.D., Graham B.S., Keefer M.C., McElrath M.J., Self S.G., Weinhold K.J., Montefiori D.C., Ferrari G., Horton H., Tomaras G.D., et al. ; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203–212 10.1097/01.qai.0000248356.48501.ff
    1. Sattentau Q.J. 2011. Vaccinology: A sweet cleft in HIV’s armour. Nature. 480:324–325 10.1038/480324a
    1. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 458:636–640 10.1038/nature07930
    1. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633–1637 10.1126/science.1207227
    1. Schell J., Rose N.F., Fazo N., Marx P.A., Hunter M., Ramsburg E., Montefiori D., Earl P., Moss B., Rose J.K. 2009. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine. 27:979–986 10.1016/j.vaccine.2008.12.017
    1. Sheppard N., Sattentau Q. 2005. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? Expert Rev. Mol. Med. 7:1–21 10.1017/S1462399405008859
    1. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204–210 10.1038/5568
    1. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., Lehrman J.K., Boaz M., Tarragona-Fiol T., Miiro G., et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337–7348 10.1128/JVI.00110-09
    1. Sreepian A., Permmongkol J., Kantakamalakul W., Siritantikorn S., Tanlieng N., Sutthent R. 2009. HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. J. Immune Based Ther. Vaccines. 7:5 10.1186/1476-8518-7-5
    1. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. 2004. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 12:193–204
    1. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 17:1757–1765 10.1089/08892220152741450
    1. Strokappe N., Szynol A., Aasa-Chapman M., Gorlani A., Forsman Quigley A., Hulsik D.L., Chen L., Weiss R., de Haard H., Verrips T. 2012. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE. 7:e33298 10.1371/journal.pone.0033298
    1. Sundling C., Forsell M.N., O’Dell S., Feng Y., Chakrabarti B., Rao S.S., Loré K., Mascola J.R., Wyatt R.T., Douagi I., Karlsson Hedestam G.B. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003–2017 10.1084/jem.20100025
    1. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 329:112–124 10.1016/j.jim.2007.09.017
    1. Traina-Dorge V., Pahar B., Marx P., Kissinger P., Montefiori D., Ou Y., Gray W.L. 2010. Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine. 28:6483–6490 10.1016/j.vaccine.2010.07.018
    1. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100–1108
    1. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615–622 10.1038/nm1244
    1. Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., Reynes J.M., Lopalco L., Bomsel M. 2009. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2:412–426 10.1038/mi.2009.89
    1. Vaine M., Wang S., Liu Q., Arthos J., Montefiori D., Goepfert P., McElrath M.J., Lu S. 2010. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS ONE. 5:e13916 10.1371/journal.pone.0013916
    1. VanCott T.C., Mascola J.R., Kaminski R.W., Kalyanaraman V., Hallberg P.L., Burnett P.R., Ulrich J.T., Rechtman D.J., Birx D.L. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319–4330
    1. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., Moore J.P. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343–346 10.1038/nm833
    1. Verkoczy L., Kelsoe G., Moody M.A., Haynes B.F. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23:383–390 10.1016/j.coi.2011.04.003
    1. Verrier F., Burda S., Belshe R., Duliege A.M., Excler J.L., Klein M., Zolla-Pazner S. 2000. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J. Virol. 74:10025–10033 10.1128/JVI.74.21.10025-10033.2000
    1. Walker L.M., Burton D.R. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358–366 10.1016/j.coi.2010.02.012
    1. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. ; Protocol G Principal Investigators 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285–289 10.1126/science.1178746
    1. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., et al. ; Protocol G Principal Investigators 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 477:466–470 10.1038/nature10373
    1. Watkins J.D., Siddappa N.B., Lakhashe S.K., Humbert M., Sholukh A., Hemashettar G., Wong Y.L., Yoon J.K., Wang W., Novembre F.J., et al. 2011. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE. 6:e18207 10.1371/journal.pone.0018207
    1. Weiss R.A., Clapham P.R., Cheingsong-Popov R., Dalgleish A.G., Carne C.A., Weller I.V., Tedder R.S. 1985. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 316:69–72 10.1038/316069a0
    1. Weiss R.A., Clapham P.R., Weber J.N., Dalgleish A.G., Lasky L.A., Berman P.W. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 324:572–575 10.1038/324572a0
    1. West A.P., Jr, Diskin R., Nussenzweig M.C., Bjorkman P.J. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083–E2090 10.1073/pnas.1208984109
    1. Willey S., Aasa-Chapman M.M. 2008. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 16:596–604 10.1016/j.tim.2008.08.008
    1. Wilson C., Reitz M.S., Jr, Aldrich K., Klasse P.J., Blomberg J., Gallo R.C., Robert-Guroff M. 1990. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol. 64:3240–3248
    1. Wright P.F., Mestecky J., McElrath M.J., Keefer M.C., Gorse G.J., Goepfert P.A., Moldoveanu Z., Schwartz D., Spearman P.W., El Habib R., et al. ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group 2004. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J. Infect. Dis. 189:1221–1231 10.1086/382088
    1. Wrin T., Nunberg J.H. 1994. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS. 8:1622–1623 10.1097/00002030-199411000-00017
    1. Wrin T., Loh T.P., Vennari J.C., Schuitemaker H., Nunberg J.H. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39–48
    1. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856–861 10.1126/science.1187659
    1. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., Sodroski J. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634–4642 10.1128/JVI.76.9.4634-4642.2002
    1. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., Shao Y., Feng Y.R., Wang L., Mathy N., et al. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. USA. 104:10193–10198 10.1073/pnas.0608635104
    1. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811–817 10.1126/science.1192819
    1. Zhou M., Kostoula I., Brill B., Panou E., Sakarellos-Daitsiotis M., Dietrich U. 2012. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine. 30:1911–1916 10.1016/j.vaccine.2012.01.026
    1. Zolla-Pazner S., Lubeck M., Xu S., Burda S., Natuk R.J., Sinangil F., Steimer K., Gallo R.C., Eichberg J.W., Matthews T., Robert-Guroff M. 1998a. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052–1059
    1. Zolla-Pazner S., Xu S., Burda S., Duliege A.M., Excler J.L., Clements-Mann M.L. 1998b. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J. Infect. Dis. 178:1502–1506 10.1086/314452

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit